Clinical trials: Vascular Complications
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Chronic Kidney Disease
Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria
This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in…
- Trial name
- NCT06150924
- Where
- 44 sites in United States
- Volunteers
- 60 people
- Sponsor
- Mineralys Therapeutics Inc.
Diabetic Foot Ulcers
The Mechanism of Action of the Unite Biomatrix in Diabetic Foot Ulcer
The purpose of this study is to assess the mechanism of action of the Unite Biomatrix and compare its performance with the standard of care, saline moistened gauze, for the treatment of diabetic foot ulcers.
- Trial name
- NCT00958711
- Testing
- Unite Biomatrix, Saline and Gauze
- Where
- 11 sites in United States
- Volunteers
- 90 people
- Sponsor
- Baxter Healthcare Corporation
IgAN, IgAVN
Study of Ravulizumab in Pediatric Participants With Primary IgAN
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or…
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis
- Trial name
- NCT07024563
- Testing
- Ravulizumab
- Where
- 15 sites in United States, China and 5 more
- Volunteers
- 36 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diabetic Foot, Peripheral Arterial Disease
Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease
Study PDA-002-DFU-003 is a Phase 2, multicenter, randomized, double blind, placebo-controlled, dose range finding study in subjects who have diabetic foot ulcer (DFU) with peripheral arterial disease (PAD).
- Trial name
- NCT02460081
- Testing
- PDA-002
- Where
- United States
- Sponsor
- Celularity Incorporated
Wounds and Injuries, Negative Pressure Therapy
Comparison of Wound Healing Between MedCu Dressings With Copper Oxide and Negative Pressure Wound Therapy Treatment
Randomized multisite two arms study in which one arm of patients will be treated with Negative Pressure Wound Therapy (NPWT) known also as Vacuum-assisted closure (VAC) treatment ("VAC Arm") and the second arm of patients will be…
- Conditions
- Wounds and Injuries, Negative Pressure Therapy, Diabetic Foot Ulcer
- Trial name
- NCT05215730
- Testing
- MedCu wound dressings with copper oxide (COD)
- Where
- Israel
- Volunteers
- 46 people
- Sponsor
- MedCu Technologies Ltd.
Diabetic Foot Ulcers
A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers
The Sponsor of this study, SANUWAVE, Inc., has developed an investigational device known as the dermaPACE® (Pulsed Acoustic Cellular Expression) device for the possible treatment of diabetic foot ulcers.
- Trial name
- NCT01824407
- Testing
- Electrohydraulic-generated shock wave
- Where
- 19 sites in United States, Canada
- Volunteers
- 90 people
- Sponsor
- SANUWAVE, Inc.
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 20 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
This study is conducted to evaluate the safety of a single intravitreal injection of THR-149.
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT03511898
- Testing
- THR-149 dose level 1, THR-149 dose level 2, THR-149 dose level 3
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- ThromboGenics
Diabetic Foot Ulcer
Affinity Prospective Diabetic Foot Trial Crossover Group
This study is an extension of the randomized controlled trial NT-DFU-AFF-01. Subjects that were randomized to the Standard of Care group will be able to crossover to the NT-DFU-AFF-02 trial and receive Affinity fHSAM if certain…
- Trial name
- NCT03205436
- Testing
- Affinity human amniotic membrane
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Organogenesis
Wounds and Injuries, Burns
ACTICOAT™ for the Treatment of Burns and Chronic Wounds
The aim of the study is to evaluate participant reported quality of life, safety, and overall performance with ACTICOAT in a clinical setting.
- Conditions
- Wounds and Injuries, Burns, Pressure Ulcer, Foot Ulcer
- Trial name
- NCT02852148
- Testing
- ACTICOAT
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Smith & Nephew, Inc.
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or…
- Trial name
- NCT00660309
- Testing
- Aliskiren, Irbesartan, Captopril
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Novartis
Relapsed Multiple Myeloma, End-stage Renal Disease
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
The purpose of this study is to see how the body and the cancer react to carfilzomib, including measuring the amount of the study drug in the blood at certain times following dosing.
- Trial name
- NCT01949532
- Testing
- Carfilzomib
- Where
- 13 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- Amgen
Diabetic Retinopathy, Diabetic Eye Problems
Validation Study of RETINA-AI Galaxy™, an Automated Diabetic Retinopathy Screening Device
Diabetes affects approximately 35 million Americans, each of whom needs at least one retinal exam per year. However, majority do not get their eye exam due to multiple prohibitive factors such as cost, transportation, difficulty…
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04774822
- Testing
- Color Fundus Photography, Mydriatics Agent, Optical Coherence Tomography (OCT)
- Where
- 3 sites in United States
- Volunteers
- 397 people
- Sponsor
- RETINA-AI Health, Inc.
Complication of Renal Dialysis, End Stage Renal Disease
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
The objective of this study is to evaluate efficacy and safety outcomes following use of the Sirolimus-eluting Collagen Implant (SeCI) in subjects undergoing surgical creation of an AV fistula for vascular access (index…
- Conditions
- Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD
- Trial name
- ACCESS (NCT02513303)
- Testing
- Sirolimus, AV Fistula Surgery, Sirolimus-eluting Collagen Implant (SeCI)
- Where
- 4 sites in United States
- Volunteers
- 269 people
- Sponsor
- Vascular Therapies, Inc.
Diabetic Foot Ulcers (DFUs)
Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD)
Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment of diabetic foot ulcers
- Trial name
- ONWARD (NCT07438951)
- Testing
- ConvaNiox
- Where
- United Kingdom
- Volunteers
- 102 people
- Sponsor
- ConvaTec Inc.
Diabetic Foot Ulcer
Evaluation of AUP12602-C as New Topical Treatment for DFUs (DIAMEND STUDY)
This is a phase 2 study performed in diabetic foot ulcer (DFU) patients with chronic non-healing, neuro-ischemic wounds to investigate the safety, tolerability and efficacy of AUP1602-C.
- Trial name
- NCT06111183
- Testing
- AUP1602-C
- Where
- 10 sites in Germany, Italy and 1 more
- Volunteers
- 64 people
- Sponsor
- Aurealis Oy
Diabetic Foot Ulcer, Infection
Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers
This is an open label study of subjects who have failed Protocol PGN-1300. Adult subjects (greater than 18 years old) who present with a mildly infected diabetic foot ulcer (IDSA criteria) having full thickness (i.e., through the…
- Trial name
- NCT02119754
- Testing
- Plurogel PN
- Where
- 15 sites in United States
- Volunteers
- 15 people
- Sponsor
- PluroGen Therapeutics, Inc
Neurologic Disorders, Nervous System Diseases
Neurologic Stem Cell Treatment Study
This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will…
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders
- Trial name
- NEST (NCT02795052)
- Testing
- Intravenous and Intranasal BMSC
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 500 people
- Sponsor
- MD Stem Cells
Diabetic Foot Ulcers
Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers
This is a Phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the clinical efficacy and safety of Antimicrobial Peptide PL-5 Topical Spray in patients with mild infections of diabetic foot…
- Trial name
- PL-5 (NCT06189638)
- Where
- 3 sites in United States
- Volunteers
- 90 people
- Sponsor
- Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.